BioSpace News Archive

InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has joined the Worldwide Innovative Network (WIN) Consortium and the Foundation for the National Institutes of Health’s Biomarker Consortium.

Royal Biologics (Hackensack, NJ), a company specializing in Advanced Cellular Technologies & Enhanced Autologous Healing, announces today the FDA 510K regulatory clearance and U.S. commercial launch of the MAXX™-BMC system.

Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd. and Levena Biopharma, a subsidiary of Sorrento Therapeutics, Inc., announced the planned presentation of A166 data in patients with HER2-expressing locally advanced or metastatic solid tumors at the 2022 Annual Meeting of ASCO, the American Society of Clinical Oncology, to be held on June 3-7 in Chicago, IL.

Recardio’s Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data suggesting potential positive effects on cardiac function and were presented in May at the World Congress on Acute Heart Failure 2022 in Madrid.

Standigm Inc. (“Standigm”), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research.

Propanc Biopharma, Inc. announced that Chief Scientific Officer and Co-Founder, Dr Julian Kenyon MD, MB, ChB, believes the reduced toxicity of PRP compared to standard treatment approaches will impact cancer patient lives significantly.

MyOme, a clinical whole genome platform analysis company, today announced new data on a cross ancestry polygenic risk score (caPRS) for breast cancer that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Two sports medicine surgeons at Hospital for Special Surgery in New York City are among the first in the nation to use an innovative new implant for the treatment of anterior cruciate ligament tears, which was recently approved by the U.S. Food and Drug Administration.

Australian life science company, QBiotics will showcase positive efficacy data from its completed phase I trial of lead cancer molecule, tigilanol tiglate, and its Phase II clinical program at Bio 2022, the world’s largest gathering of biotechnology and pharma leaders.

AbbVie (NYSE: ABBV) today announced the presentation of full results from two studies from the Phase 3 SELECT-AXIS 2 program evaluating upadacitinib (RINVOQ®).